Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
Launched by UNIVERSITY OF MICHIGAN · Jun 28, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different programs aimed at helping older patients in the hospital avoid delirium, which is a sudden change in mental status that can cause confusion and disorientation. The trial compares the standard Hospital Elder Life Program (HELP) with a new version called Family-Augmented HELP (FAM-HELP), which includes family members or caregivers to provide additional support. The main goals are to see which program is better at preventing delirium and improving the experiences of both patients and their families during hospital stays.
To be eligible for this trial, participants must be at least 70 years old, expect to stay in the hospital for at least three days, and have a family member or caregiver who can be present in the hospital. They should also have at least one factor that makes them at risk for delirium, such as memory problems or dehydration. However, those who are already experiencing delirium when they arrive at the hospital or cannot communicate will not be included. If you join the study, you can expect to receive either the standard HELP or the FAM-HELP program, both designed to enhance your care and support during your hospital stay.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of informed consent
- • At least 70 years of age
- • Anticipated length of hospital stay at least 72 hours
- • Family member or care partner available to be on-site in the hospital
- • At least one delirium risk factor (e.g., cognitive or functional impairment, dehydration, vision or hearing impairment)
- • Evaluable cognitive function at baseline (i.e., ability to complete baseline cognitive function assessment)
- Exclusion Criteria:
- • Delirium on admission
- • Unable to communicate verbally (e.g., coma, mechanical ventilation)
- • Unable to participate fully in interventions (e.g., terminal condition, advanced dementia)
- • Staff safety concerns (e.g., violent behavior)
- • Cardiac or intracranial surgery (due to competing causes of delirium)
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Madison, Wisconsin, United States
Pittsburgh, Pennsylvania, United States
Salt Lake City, Utah, United States
Pittsburg, Pennsylvania, United States
Ann Arbor, Michigan, United States
Orange, California, United States
Portland, Maine, United States
Patients applied
Trial Officials
Sharon K Inouye, MD
Principal Investigator
Hebrew SeniorLife
Phillip E Vlisides, MD
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported